While statins remain the gold standard for lowering lipid levels and reducing cardiovascular risk, their benefits come with a well-documented caveat: a 9% to 13% increased risk of developing new-onset type 2 diabetes mellitus (NO-T2DM).
While researchers have long known that genetic variations play a role in how patients respond to these drugs, the exact genetic architecture behind statin-induced diabetogenesis has remained elusive. Now, a new matched case-control study highlights the role of specific genetic variations in the statin target gene, HMGCR, in modulating this risk.
Unlocking the Genetic Link
The study focused on four common variants within the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene—the direct pharmacological target of statins—as well as a key variant in the SLCO1B1 gene (rs4149056), which encodes a hepatic transporter crucial for statin uptake.
Researchers evaluated 194 adult patients receiving either atorvastatin or rosuvastatin. The cohort was split evenly:
- Cases (n = 97): Patients who developed NO-T2DM within four years of starting statin therapy.
- Controls (n = 97): Patients who remained diabetes-free after four years of statin use.
To isolate the genetic variables, the participants were meticulously matched for age, sex, ethnicity, body mass index (BMI), and statin intensity.
Key Findings: Protections in the Haplotypes
The individual single-nucleotide polymorphisms (SNPs) yielded some intriguing, albeit modest, results. Specifically, the HMGCR variant rs17238484 showed a nominal protective effect.
- Carriers of the T allele (GT + TT) had a lower risk of developing diabetes compared to those with the GG genotype (OR = 0.56, 95% CI: 0.36–0.99, P = 0.044).
- Note: This association did not withstand strict statistical correction for multiple testing.
However, the signal became much stronger when researchers looked at haplotypes—groups of genes inherited together from a single parent.
| Genetic Marker | Analysis Type | Key Outcome | Statistical Strength |
|---|---|---|---|
| rs17238484 (T allele) | Single SNP | Nominal reduction in NO-T2DM risk | OR = 0.56 (Loses significance after multiple-testing correction) |
| T–T–T Haplotype |
(rs17671591–rs17238484–rs12916)|Haplotype|Significant reduction in NO-T2DM risk|OR = 0.12 (95% CI: 0.02–0.58, P = 0.009)|
|SLCO1B1 (rs4149056)|Single SNP|No significant association with diabetes risk|N/A|
The T–T–T haplotype of rs17671591–rs17238484–rs12916 stood out as a potentially powerful biomarker, showing a profound correlation with a decreased risk of developing diabetes while on statin therapy. Conversely, the heavily studied hepatic transporter variant SLCO1B1 (rs4149056) showed no significant association with NO-T2DM in this cohort.
Moving Toward Precision Cardiovascular Medicine
The Big Picture: While statins are life-saving medications for cardiovascular health, understanding who is at risk for metabolic side effects is critical for personalized medicine.
The findings suggest that looking at combinations of genetic variants (haplotypes) rather than isolated SNPs may offer much deeper insights into how a patient’s body will react to long-term statin therapy. Because the study was limited to 194 patients, the authors emphasize that larger, more diverse population studies are urgently needed to validate these genetic signatures before they can be deployed as clinical screening tools.